MannKind Corporation Stock Nasdaq
Equities
US56400P2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-08 | Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 | MT |
Sales 2024 * | 272M 371M | Sales 2025 * | 319M 433M | Capitalization | 1.25B 1.7B |
---|---|---|---|---|---|
Net income 2024 * | 35M 47.63M | Net income 2025 * | 70M 95.26M | EV / Sales 2024 * | 3.68 x |
Net cash position 2024 * | 248M 338M | Net cash position 2025 * | 273M 371M | EV / Sales 2025 * | 3.07 x |
P/E ratio 2024 * |
39.9
x | P/E ratio 2025 * |
20.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on MannKind Corporation
Managers | Title | Age | Since |
---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 47 | 16-03-13 |
Sanjay Singh
CTO | Chief Tech/Sci/R&D Officer | 57 | 22-09-30 |
Kevin Kaiserman
CTO | Chief Tech/Sci/R&D Officer | - | 20-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 18-11-26 | |
Anthony Hooper
BRD | Director/Board Member | 69 | 19-12-31 |
Ronald Consiglio
BRD | Director/Board Member | 80 | 03-09-30 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |